Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) Shareholder Yield % : -16.78% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03378 Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
11 GF Score
Price HK$27.56
! 1 Warning Sign
View Full Analysis

What is Hanx Biopharmaceuticals (Wuhan) Co Shareholder Yield %?

Hanx Biopharmaceuticals (Wuhan) Co HKSE:03378 +6.00% 11 Shareholder Yield % is -16.78% as of Dec. 2025. GuruFocus rates HKSE:03378 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,295 Biotechnology companies, Hanx Biopharmaceuticals (Wuhan) Co ranks worse than 76.6% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % was -16.78%.


Hanx Biopharmaceuticals (Wuhan) Co  (HKSE:03378) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Hanx Biopharmaceuticals (Wuhan) Co Shareholder Yield % Related Terms


Hanx Biopharmaceuticals (Wuhan) Co Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanx Biopharmaceuticals (Wuhan) Co Shareholder Yield % Chart

Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend Dec23 Dec24 Dec25
Shareholder Yield %
0.00 0.00 -28.58

Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23 Dec24 Dec25
Shareholder Yield % 0.00 0.00 -28.58

HKSE:03378 vs VRTX, REGN, RVMD: Shareholder Yield % Comparison

For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanx Biopharmaceuticals (Wuhan) Co Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % falls into.


HKSE:03378
11GF Score
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hanx Biopharmaceuticals (Wuhan) Co Shareholder Yield % Calculation

Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-26.32 %+-2.26 %
=-28.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -16.78% mean?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a Shareholder Yield % of -16.78% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. According to the industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #992 out of 1295 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % too high?
Hanx Biopharmaceuticals (Wuhan) Co's current Shareholder Yield % is -16.78%. Based on the distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #992 out of 1295 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #992 out of 1295 companies for Shareholder Yield %. This places Hanx Biopharmaceuticals (Wuhan) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current Shareholder Yield % is -16.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current Shareholder Yield % of -16.78%. The current Shareholder Yield % is -16.78%. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current Shareholder Yield % is -16.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hanx Biopharmaceuticals (Wuhan) Co Business Description

Address No. 1 Jiufeng 1st Road, Building A8, Phase II, Bio-Innovation Park, East Lake New Technology Development Zone, Hubei, Wuhan, CHN
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score

Get the complete analysis for HKSE:03378

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.56
Price